ACC 2023 – Esperion’s outcomes win looks lacklustre
A 13% reduction in the risk of cardiovascular events is statistically significant but not spectacular.
No Blys for Vera
Atacicept hits in phase 2, but uncompetitive data are seen as good news for its IgAN rivals.
Not so fast for some accelerated approvals
The US conditional approval pathway has enjoyed years of expansion, but now the FDA is trying to put the toothpaste back into the tube.
Merck opens its mind to epigenetics with Imago buy
The purchase sets up another showdown with the group’s old rival, Bristol Myers Squibb, in LSD1 inhibition.
AHA 2022 – History repeats for Medtronic
The company’s renal denervation system has failed in a crucial late-stage trial, just as an earlier version did eight years ago.
TCT 2022 – Otsuka’s renal denervation system shines
Paradise is now odds-on for US approval – but Medtronic’s rival device is not far behind.
Go or no go? Bristol’s Tyk2 test
A green light from the FDA is expected for deucravacitinib, while Amylyx, Ferring and Oncopeptides head for panels.
